Determination of bile acids from human gallbladder by 1 H-MRS-Protocol optimization and estimation of reproducibility

Concentration of Gallbladder Phosphatidylcholine in Cholangiopathies: A Phosphorus-31 Magnetic Resonance Spectroscopy Pilot Study

BACKGROUND

Biliary phosphatidylcholine (PtdC) concentration plays a role in the pathogenesis of bile duct diseases. In vivo phosphorus-31 magnetic resonance spectroscopy (³¹ P-MRS) at 7 T offers the possibility to assess this concentration noninvasively with high spectral resolution and signal intensity.

PURPOSE

Comparison of PtdC levels of cholangiopathic patient groups to a control group using a measured T₁ relaxation time of PtdC in healthy subjects.

STUDY TYPE

Case control.

SUBJECTS

Two patient groups with primary sclerosing cholangitis (PSC, 2f/3 m; age: 43 ± 7 years) and primary biliary cholangitis (PBC, 4f/2 m; age: 57 ± 6 years), and a healthy control group (CON, 2f/3 m; age: 38 ± 7 years). Ten healthy subjects for the assessment of the T₁ relaxation time of PtdC.

FIELD STRENGTH/SEQUENCE

A 3D phase-encoded pulse-acquire ³¹ P-MRSI sequence for PtdC quantification and a 1D image-selected in vivo ³¹ P spectroscopy for T₁ estimation at 7 T, and a T2-weighted half-Fourier single-shot turbo spin echo MRI sequence for volumetry at 3 T.

ASSESSMENT

Calculation of gallbladder volumes and PtdC concentration in groups using hepatic gamma-adenosine triphosphate signal as an internal reference and correction for insufficient relaxation of PtdC with a T₁ value assessed in healthy subjects.

STATISTICAL TESTS

Group comparison of PtdC content and gallbladder volumes of the PSC/PBC and CON group using Student's t-tests with a significance level of 5%.

RESULTS

PtdC T₁ value of 357 ± 85 msec in the gallbladder. Significant lower PtdC content for the PSC group, and for the female subgroup of the PBC group compared to the CON group (PSC/CON: 5.74 ± 0.73 mM vs. 9.64 ± 0.97 mM, PBC(f)/CON: 5.77 ± 1.44 mM vs. 9.64 ± 0.97 mM). Significant higher gallbladder volumes of the patient groups compared to the CON group (PSC/CON: 66.3 ± 15.8 mL vs. 20.9 ± 2.2 mL, PBC/CON: 49.8 ± 18.2 mL vs. 20.9 ± 2.2 mL).

DATA CONCLUSION

This study demonstrated the application of a ³¹ P-MRSI protocol for the quantification of PtdC in the human gallbladder at 7 T. Observed differences in PtdC concentration suggest that this metabolite could serve as a biomarker for specific hepatobiliary disorders.

LEVEL OF EVIDENCE

2 TECHNICAL EFFICACY STAGE: 3.